Daiichi Move Aids Global Competition With U.S., Israel
This article was originally published in PharmAsia News
Executive Summary
The move by Japan's Daiichi Sankyo to buy India's largest pharmaceutical firm, Ranbaxy Laboratories, is seen as aiding the Japanese firm's efforts to compete with U.S. and Israeli rivals in the global drug market. By merging with Ranbaxy, Daiichi becomes the world's 15th largest drug maker, giving it access to Ranbaxy's generics empire, particularly in the United States where Daiichi has not been much of a player. By buying Ranbaxy, Daiichi is positioning itself in the U.S. market to be a major supplier in a generics market that comprises nearly half of U.S. prescriptions. (Click here for more
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.